Patients with head and neck cancer (HNC) experience increased risk of depression and compromised quality of life. Identifying patients with HNC at risk of depression can help establish targeted interventions.
D epression has been reported to be one of the most common adverse effects associated with the diagnosis and treatment of cancer. Studies indicate that as many as 49% of patients with cancer meet the diagnostic criteria for some form of depression. 1 Clinical depression or depressive symptoms can present a number of challenges throughout cancer treatment and recovery for both clinicians and patients. [2] [3] [4] However, because concerns are often focused on the physical needs of the patients and because the treating physicians are often ill equipped to recognize and manage depression, depression is often underrecognized in oncology populations. 5 Head and neck cancers (HNCs) are among the most challenging cancers in terms of their effects on survivors. 6 Treatment of these cancers can be extremely invasive and can cause long-term adverse effects, functional deficits, and permanent disfigurement. 7 Major depression can be a serious consequence of HNC and its treatment. 8 Patients who develop depression are less likely to complete treatment, leading to subsequent increased mortality. 9, 10 Furthermore, patients with HNC who develop depression during HNC treatment have been shown to have poorer quality of life following treatment. 4 Therefore, preventing depression in patients with HNC represents an enormous opportunity to effect the overall course of the disease and improve the quality of life of patients.
We have previously reported our results of a randomized clinical trial aimed at examining whether depression could be prevented in patients with HNC undergoing primary curative therapy. 11 The purpose of that study, the Prevention of Depression in Patients Being Treated for Head and Neck Cancer Trial (PROTECT), was to investigate the effect of prophylactic administration of the antidepressant escitalopram oxalate on the prevention of major depression in patients who were diagnosed as having HNC, who were not diagnosed as having depression at baseline, and who were about to begin cancer treatment. 11 The trial showed that compared with patients receiving placebo, patients randomized to escitalopram had a greater than 50% lower incidence of depression. Although the findings from PROTECT suggested a strategy of prophylactic antidepressant use for all patients with HNC and without depression prior to starting cancer treatment, those results also prompted an examination of whether other factors may be identified at treatment initiation that may enable more targeted interventions in the future. The objective of the present ad hoc study was to examine the baseline characteristics of the PROTECT population to identify potential factors associated with moderate or greater depression in real-world patients with HNC but without baseline depression.
Methods

Study Design and Intervention
The detailed methods used in PROTECT have been previously published, 11 the full trial protocol is provided in Supplement 1, and a brief summary is provided herein. For PROTECT, we conducted a randomized, double-blind, placebo-controlled clinical trial of escitalopram treatment among patients without depression who were about to undergo treatment of HNC (ClinicalTrials.gov identifier NCT00536172). Participants were eligible if they were older than 18 years with new or recurrent stages II through IV epidermoid carcinoma of the head and neck. Exclusion criteria were cognitive impairment, systemic metastatic cancer, other conditions that limited life expectancy to 6 months or less, psychosis, schizophrenia, major depressive disorder, current treatment of anxiety or depression, persistent inability to communicate, uncontrolled pain, current participation in another research study receiving therapy, or women who were pregnant, nursing, or not practicing reliable birth control. The study was conducted at an academic medical center and a community cancer center, with institutional review board approval from the University of Nebraska Medical Center and the Nebraska Methodist Hospital. All participants provided written informed consent. Participants were stratified by study site, sex, cancer stage (early [stage II] vs advanced [stage III or IV]), primary modality of treatment (radiotherapy with or without chemotherapy vs surgery with or without radiotherapy), and randomization to placebo or escitalopram and balanced within these strata. The trial design sought to maximize safety in this population, which has an elevated risk of suicide. Thus, participants exited the study at the first instance they met the primary end point of moderate depression on a self-rated measure. Participants were also withdrawn if they reported suicidal ideation or intent or had a diagnosis of major depression as assessed using the Mini-International Neuropsychiatric Interview depression module.
All patients received standard clinical psychosocial interventions throughout the study as well as education and counseling from physicians and nurses as needed. Per the standard practice of the clinic, participants were offered the opportunity to join a monthly support group but did not receive formal psychotherapy.
administered at baseline and subsequent weeks. A QIDS-SR score of 11 or higher was indicative of moderate or greater depression. The clinician-rated version of the QIDS was also given at each rating period. At baseline, participants were screened for psychiatric illness using the Mini-International Neuropsychiatric Interview.
Choice of Variables
Variables to investigate were selected based on those previously reported in the literature. These variables included patient age at diagnosis, sex, educational level, place of residence (urban or rural), tumor site, stage of cancer, primary treatment modality (surgery or radiotherapy), history of depression or other psychiatric diagnosis, previous treatment of depression or suicide attempt, family history of depression, suicide, or suicide attempt, and baseline number of symptoms reported on the QIDS-SR and clinician-rated QIDS. 8, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 
Statistical Analysis
We analyzed data from the baseline visit to determine whether any of the variables were associated with development of moderate or greater depression (primary end point of the study). Because the patient group receiving placebo most closely represented the real-world scenario of patients newly diagnosed as having HNC who have no baseline depression and who are not receiving prophylaxis against development of depression, data for the placebo group were specifically evaluated to determine the cutoff values for the baseline QIDS-SR score and other patient-and treatment-related factors associated with the primary end point. Continuous variables were analyzed using paired t tests, and categorical variables were analyzed using Fisher exact tests or 2-tailed χ 2 tests. Multivariable receiver operating characteristic (ROC) analyses were used to identify the optimum cutoff points for the development of depression. A 2-sided P < .05 was considered statistically significant, and odds ratios are presented with exact 95% CIs. Data analyses were conducted from May 2016 to April 2017 using SAS, version 9.3 (SAS Institute Inc).
Results
Patients were screened from January 2008 to December 2011, with 160 agreeing to participate. Twelve of those potential participants did not meet the eligibility criteria; thus, 148 patients were randomized, 74 each to the escitalopram and placebo arms. Table 1 summarizes the clinical and demographic characteristics of the study population.
Of the 148 randomized patients, 125 were evaluable, with 60 patients receiving prophylactic escitalopram and the remaining 65 receiving placebo. Twenty-two patients developed moderate or severe depression during the course of the study (16 in the placebo group and 6 in the escitalopram group). The results of our previous analyses 11 indicated those patients with HNC who received radiotherapy as their initial therapy were significantly more likely to develop depression than patients who were surgically treated (radiotherapy group compared with surgery group hazard ratio, 3.6; 95% CI, 1.38-9.40). The eTable in Supplement 2 gives the bivariate analysis results of selected clinical and demographic variables by the primary depression end point for all patients included in the study, irrespective of treatment arm. The only baseline patient variable that was shown to be associated with the outcome of development of moderate or severe depression was the QIDS-SR score at baseline. The mean baseline QIDS-SR scores of those who developed moderate or greater depression during the study period were significantly higher than the baseline scores of those individuals who did not develop depression during the study period (6.2 vs 4.2, respectively [difference, 2.0; 95% CI for difference, 0.9-3.0]).
The eFigure in Supplement 2 shows the side-by-side boxplot of the baseline QIDS-SR scores by depression outcome (independent of treatment arm) during the study period. In total, 7 of the 125 participants (approximately 6%) had a score of 0 or 1 on the QIDS-SR at baseline and were in the group of patients who did not develop moderate or greater depression during the course of the study. The baseline QIDS-SR scores ranged from 0 to 9 for individuals who did not develop depression and from 2 to 10 for individuals who developed moderate or greater depression during the study period. The eFigure in Supplement 2 shows that baseline scores for patients who developed moderate or greater depression were higher than those for patients who were free of depression during follow-up. Furthermore, no one who developed the depression outcome of interest had a baseline score of less than 2 at the time of treatment initiation, and 20 of 22 (90.9%) patients who developed depression in the entire study cohort had a baseline QIDS-SR score of 4 or greater.
Other factors that were not associated with the subsequent development of moderate or greater depression included patient age, sex, rural vs urban residence, educational level, clinical stage, cancer site, having a family or personal history of depression, and having a history of suicide attempt or psychiatric illness. We performed additional analyses to consider clinical factors that may be significant specifically in the placebo group. Table 2 gives the bivariate analysis results of selected clinical and demographic variables by the primary end point among patients receiving no prophylactic intervention for prevention of depression.
In the placebo group, development of moderate or severe depression was associated with type of initial treatment (primary radiotherapy) and QIDS-SR score at baseline. In this group, 12 of 31 patients (39%) who received radiation as part of their initial course of treatment developed depression during the study period compared with only 4 of 34 patients (12%) who did not receive radiotherapy as part of their initial treatment strategy (odds ratio, 4.74; CI, 1. 33-16.85 ). In addition, mean baseline QIDS-SR scores for patients who received placebo and developed moderate or greater depression during the study period were significantly higher than the baseline scores of those individuals who did not develop depression during the study period (6.5 vs 4.0, respectively; difference, 2.5; CI for the difference, 1.3-3.7).
On the basis of the bivariate analysis results, multivariable ROC analyses were conducted using baseline QIDS-SR score and initial treatment as factors in the placebo group. The results of the multivariable ROC analyses for the placebo group are shown in the Figure and Table 3 .
For the placebo group, the area under the curve (AUC) for the model that included both variables (0.904) had significantly better fit than models with either baseline QIDS-SR scores (AUC, 0.816; 95% CI, 0.696-0.935) or initial treatment selection (AUC, 0.681; 95% CI, 0.552-0.811) alone.
The suggested cutoff values are the model-determined probability values that minimize the distance between the ROC curve and point (0, 1), maximize the vertical distance between the ROC curve and the diagonal reference line, or both. Using the optimal cutoff for the combined model produced a sensitivity of 0.938 with a specificity of 0.755 in the placebo group (Table 4) . For the placebo group, using the QIDS-SR score as a factor associated with developing moderate or severe depression, we found that a score threshold of 6 provided a sensitivity of 0.69 and a specificity of 0.86. When a score threshold of 4 was used, the sensitivity was 0.94 and the specificity was 0.43. A score threshold of 2 improved the sensitivity to 1.00, with an expected decrease in specificity.
Discussion
The risks of failing to treat depression in HNC are stark and multiple: decreased compliance with treatment, 9 decreased quality of life, 13 and increased mortality. 23 In addition, HNC is associated with a higher risk of suicide compared with most other cancer sites and compared with the general population. 24 In our previously published trial reports, 11, 25 we showed that prophylactic use of escitalopram could reduce the number of patients who met the predetermined criteria for moderate or severe depression. As with all prevention strategies, the goal is to minimize the number of people who are exposed to the risk of the drug while maximizing the number who benefit. Although our previous study provides an important finding, prophylactic treatment of all patients who are starting treatment of HNC will mean unnecessary administration of the drug to some patients who may not develop depression. The number needed to treat was 6.8 when using a strategy based on offering pharmacologic prophylaxis against depression to all patients planning to initiate therapy of stages II through IV epidermoid carcinoma of the head and neck region. Therefore, in the present analysis, we examined available baseline measures that might enable us to home in on participants at increased risk thus potentially allow some targeting for this intervention. For the placebo group, baseline QIDS-SR scores and choice of initial treatment (primary radiotherapy) showed statistically significant associations with the predefined end point of development of moderate or severe depression. This finding is consistent with previous research showing a significant positive association with depressive symptoms at study onset. 26, 27 Furthermore, development of depression may be linked to the choice of initial therapy, and patients who receive initial radiation-based therapy may be particularly vulnerable. 11, 28 These patient-and treatment-related factors should alert the clinician to the potential development of depression and encourage discussion and shared decision making of management strategies, including the use of pharmacologic prophylaxis against depression. Of note, despite prophylactic therapy, some patients still progressed to develop clinically relevant depression. It is important that clinicians maintain continued surveillance for signs and symptoms of depression even among those patients who choose to receive pharmacologic prophylaxis at the outset. An important secondary finding of PROTECT was the sustained improvement in quality of life among participants who did not develop depression for up to 3 months after cessation of treatment with the drug. 11 Withholding antidepressant treatment may result in loss of these quality-of-life benefits in a patient population that is at significant risk for decline in wellbeing. It is our hypothesis that a type of posttraumatic stress reaction may have developed in the group of patients who did not receive prophylactic antidepressant treatment, particularly in the radiotherapy arm, and that this reaction may be mitigated, at least in part, by prophylactic administration of escitalopram. The implications of limiting access to prophylactic escitalopram among patients with a low QIDS-SR score, and therefore the loss of this potential advantage, must be considered when using any baseline score threshold as a measure of when to offer prophylactic escitalopram to patients with HNC. Because of the favorable safety profile and low incidence of adverse effects of escitalopram in the study population, 11 setting the cutoff at a very low number affords more patients this potential benefit while minimizing treatment-associated harm.
Although the present study showed that the baseline QIDS-SR score and initial treatment with radiotherapy were significantly associated with depression in the placebo group, we did not find support for other measures that have previously been reported to be associated with increased risk of developing moderate or greater depression, such as having a personal history of major depression or its treatment, 22 a history of other psychiatric illness, 16 a family history of major depression, 22 age, 8 sex, 27 educational level, [15] [16] [17] and stage of cancer. 17 Other variables not examined in the present study have also been shown to be associated with the development of depression in this patient population. A study by De Leeuw et al 29 examined the association of social support via social networks with depression among 197 patients with HNC. The extent of their social network was measured with 2 questions about the number of individuals in their professional and informal network (partner, family, and friends). The results of that study found that higher levels of support were associated with fewer depressive symptoms. Karnell and colleagues 30 also prospectively examined the role of social support as a risk factor of developing depression among patients with HNC. They studied 394 patients and found that ratings of perceived posttreatment social support at diagnosis were significantly associated with fewer depressive symptoms. Other studies have found that factors, including patients' coping style, overall health and physical functioning, openness of the family to discussing cancer, and size of the informal social network, may also be associated with the development of depression among patients with HNC. 26, 27 In addition, the medical comorbidities of patients with cancer or other chronic disease have been shown to be associated with the development of depression, especially among elderly patients. 31, 32 Because one of the goals in designing PROTECT was to minimize the burden of 
Limitations
Other limitations of our study include a relatively small number of participants at 1 academic center and 1 community hospital and a study design that did not collect patient data on participants after they met the depression study end point, which allowed these patients to exit the study and receive specific care for depression as medically necessary. Although not statistically significant, a higher proportion of patients in the placebo group who became depressed were nonurban residents, had some college education, received a diagnosis at a later stage, had a diagnosis of oral cancer, and had a family or personal history of depression. The present study was likely underpowered to determine whether any of these differences may have been important. Although we cannot definitively conclude whether these baseline characteristics may be associated with developing depression, this information can provide guidance for characteristics that should be considered for future study. In addition, the relatively small sample size and small proportion of patients who developed depression limited the present study to primarily univariate analyses. A more extensive multivariable analysis could help identify whether specific combinations of baseline characteristics are associated with the development of depression. This should be investigated further in future studies.
Conclusions
The present study found that, among patients who received a diagnosis of HNC, baseline depressive symptoms (as measured by the QIDS-SR score) and use of radiotherapy as a primary therapeutic modality were associated with an increased likelihood of developing moderate or severe depression during cancer treatment. These associations are clinically meaningful because they permit clinicians to better recognize at-risk patients. Moreover, these results may inform patients, their caregivers, and health care professionals when considering the risk of clinically relevant depression during treatment of HNC, the contribution of depression to survivorship experience and quality of life, and the potential strategies for prevention and mitigation of depression. Prophylactic antidepressant treatment should be strongly considered for patients who meet a threshold score of 4 on the QIDS-SR and for those who are expected to receive radiotherapy as part of their initial cancer therapy. This strategy, which attempts risk prediction, may help identify patients who may derive the most benefit from pharmacologic prophylaxis of depression. It should augment clinical discussion and decision making for clinicians who may prefer more specificity when selecting patients with HNC for administration of prophylactic antidepressants. However, this threshold may lead to a missed treatment opportunity for up to 9% of patients with HNC at risk of developing depression.
Because of the potential for profound effects of untreated depression in this patient population, it is reasonable to err on the side of sensitivity rather than specificity. By this argument, lowering the threshold for offering prophylactic antidepressant treatment to a QIDS-SR score of 2 further reduces the risk of untreated depression in patients with HNC.
Although a strategy of universal prophylaxis in the PROTECT population led to a number needed to treat of 6.8, the more selective strategy of using the low QIDS-SR score of 2 as a threshold slightly decreased the number needed to treat to 6.6. Overall, irrespective of treatment strategy, the use of prophylactic antidepressants in the present study population resulted in a relatively low number of individuals being unnecessarily treated.
Depression can substantially affect the safety and well-being of patients with HNC. Clinicians may recognize that antidepressant use for these patients, in addition to mitigating depression, may contribute to sustained improvement in quality of life.
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Prophylactic escitalopram administration should be considered for all patients who receive a diagnosis of HNC as part of their multidisciplinary care, but its use should be more strongly considered for patients who show depressive symptoms at baseline and for those expected to receive radiotherapy as their initial cancer treatment. Future research using larger sample sizes and multisite studies should continue to try to identify other clinical and social factors that may be predictive of depression. 
IV. RESEARCH PROTOCOL A. SPECIFIC AIMS
Treatment for head and neck cancer (HNC) is arduous and debilitating. As a result, up to 40% of patients develop depression, typically within the first three months of diagnosis of HNC. 1 Depression is rarely recognized or treated yet lengthens hospital stay, and reduces adherence with medical treatment, quality of life, and survival. 2, 3, 4 The most significant factor in HNC prognosis is timely completion of radiation therapy. 5 Depression can lead to delays in radiation delivery which in turn may diminish the overall prognosis. 6, 7 Depression in patients with HNC also impairs quality of life which is independently predictive of decreased long-term survival. 8, 9 Depression can also lead to suicide; patients with cancers of the larynx and tongue account for 2 of the 3 highest suicide rates among cancer patients. 10 Further, an overwhelming majority of HNC patients use alcohol and tobacco, both implicated in reducing survival yet cessation is often difficult for these patients. 11 Remarkably, there are no published studies evaluating the efficacy of antidepressants for the treatment of major depression in patients with HNC. Similarly, the impact of antidepressants on quality of life, treatment adherence and rates of alcohol and tobacco use has not been examined.
This lack of information, coupled with the relatively short window of opportunity for intervention in the first three months following diagnosis of HNC cancer, led us to investigate whether major depression could be prevented with the prophylactic use of the antidepressant citalopram initiated soon after the diagnosis of cancer. We hoped thereby to limit or prevent many serious sequelae including erosion of quality of life and delays or interruptions of treatment.
We conducted a randomized, double blind, placebo-controlled pilot trial investigating the prophylactic utility of the antidepressant citalopram in nondepressed newly diagnosed or recurrent HNC patients who were about to begin treatment. This small trial demonstrated that 40% of the subjects taking placebo over the 12 week study period developed major depression, compared with only 17% of subjects taking citalopram. Additionally, no subject who took citalopram had a clinical global impression-severity (CGI-S) score of greater than mildly ill during the pilot. Also, quality of life was significantly better preserved in the citalopram group after 16 weeks.
These promising preliminary results have led us to propose herein a larger, randomized, double-blind, placebo-controlled trial investigating the prophylactic utility of the antidepressant citalopram in nondepressed, newly diagnosed or recurrent HNC patients. Our primary hypothesis is that prophylactic treatment of nondepressed HNC patients with the antidepressant citalopram, compared to placebo, will significantly reduce the development of major depression. Secondarily, we hypothesize that treatment with citalopram, compared to placebo, will preserve quality of life, improve adherence to cancer treatment and reduce tobacco and alcohol usage.
Primary Specific Aim:
1) To determine if prophylactic citalopram, compared to placebo, will reduce the incidence of depression among non-depressed HNC patients beginning treatment for their cancer.
Secondary Specific Aims:
1) To determine if prophylactic citalopram, compared to placebo, will preserve quality of life in patients undergoing treatment for HNC.
2) To determine if prophylactic citalopram, compared to placebo, will improve HNC treatment adherence including avoiding delays and premature discontinuation of therapy.
3) To determine if prophylactic citalopram, compared to placebo, will reduce the use of alcohol and tobacco in those patients using these substances at the time of diagnosis. 
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Depression is even more common in patients with HNC, [14] [15] [16] [17] [18] [19] with the reported incidence ranging from 20-40%.
2,3,20
HNC is the collective name for cancers that affect the mouth, sinuses, pharynx, larynx, and major salivary glands, 95% of which are epidermoid carcinomas. 21 In addition to known risk factors for depression, such as personal or family history of depression, there are several factors unique to HNC, which make this patient population particularly vulnerable to psychiatric complications. [22] [23] [24] [25] [26] [27] [28] These include aggressive and lengthy treatment strategies, morbid effects from the disease and its treatment, high rates of alcohol and tobacco use, and personality characteristics that may predispose these individuals to psychopathological morbidity. 9 Standard treatment for HNC depends on the stage of disease at presentation. Early stage cancer (I and II) occurs in about 40% of all patients and can be treated with a single modality (i.e. either surgery or radiation), which takes from 2 to 7 weeks. 29 Advanced stage disease (stages III and IV) requires two or three modalities (i.e. surgery, radiation and chemotherapy in various combinations) and treatment takes 7-14 weeks and generally results in more severe sequelae. 29 Surgical resection involves removing part or all of the affected organ, which may include the tongue, pharynx, larynx, mandible, maxilla, or face. The associated defects can temporarily or permanently disrupt breathing, eating, vision, and speech. 24, 25 Facial disfigurement cannot be concealed, creating significant impairment in social interactions and emotional expression, which can lead to social withdrawal and avoidance of potentially helpful support systems. 24 Radiation therapy often results in severe xerostomia, mouth ulcerations (mucositis), edema and fibrosis with resultant hoarseness, odynophagia and dysphagia. Chemotherapy is also used as an adjunct to radiation and surgery and can inflict additional hardships, such as severe fatigue, hair loss, anemia and nausea. The combination of radiotherapy and chemotherapy has a synergistic effect on the severity of mucositis and dysphagia. Recovery from these treatments is difficult and requires months of adjustment. 19 Patients who develop HNC frequently use tobacco and alcohol. Approximately 75% of patients with HNC are chronic tobacco and/or alcohol users. 31, 32 The risk is clearly synergistic, individuals that are heavy smokers (2 packs per day or more) and heavy drinkers (30 or more drinks per week) have a 37 fold increased risk of developing HNC. 32 While the risk in non-smokers is difficult to determine since most patients smoke and drink, evidence exists that heavy alcohol use alone increases the risk by 5.8 fold. 32 HNC patients with a history of tobacco and alcohol use often feel responsible for and thus deserving of their condition which creates additional anxiety. 22 Furthermore, if they are not successful in stopping the use of tobacco and/or alcohol, they may experience even more guilt and their family may feel that they are not trying. 22 This can lead to further alienation and loss of social support. Among individuals with a history of tobacco and alcohol abuse prior to developing HNC, personality characteristics of dependence, poor ability to change habits, and poor adaptive coping skills predispose them to psychological morbidity. 8, 9 Depression typically emerges during the course of treatment of HNC with peak symptoms occurring two to three months after diagnosis. 16, 26, 33 Suicide is common in this patient population. Several studies assessing the role of suicide among cancer patients demonstrate an increased age-adjusted risk in both men and women. 34, 35, 36 One study found that the risk is highest in the first three months for men and between 3 and 12 months for women and increases with a prognosis of the cancer that is perceived to be poor (which included cancers of the tongue and pharynx). 35 Another study reported that cancers of the larynx and tongue account for 19% of suicides but only 2% of all cancers. 10 A recent study estimates the suicide rate in the general population at 15.8 per 100,000 person-years. The rate in cancer patients was 33.6 per 100,000 person-years and in HNC patients the rate was 50.5 per 100,000 person-years. Thus, patients with HNC have over 3 times the risk of the general population and 1.5 times the average cancer patient's risk. 37 These remarkable statistics underscores the severity of depression in these patients.
While depression is common in patient with HNC, depressive disorders are rarely diagnosed. This is related to a number of factors, including difficulties associated with the diagnosis of depression in patients with cancer, or indeed any serious medical illness. Typically, the clinician caring for HNC patients lacks the expertise for making psychiatric diagnoses, including the identification and rating of depressive symptoms and emotional well-being. 38 Additionally, the criteria used to diagnose depression include a variety of physiological or "vegetative" symptoms, such as decreased energy, fatigue, insomnia or anorexia that can overlap with PHS 398/2590 (Rev. 09/04) Page Continuation Format Page symptoms caused by the cancer and/or its treatment. Hence, it is not surprising that antidepressants are infrequently prescribed for cancer patients. As few as 2% to as high as 14% of cancer patients receive antidepressant medication. 39, 40 Clinicians often fail to prescribe antidepressants because they assume that the depression is a natural consequence of having a severe illness or because they consider the medical illness to be a contraindication to antidepressant treatment. This conundrum deepens when clinicians feel an effective and safe treatment is not available. [41] [42] [43] Little is known about the best treatment approach for depression in cancer patients since most depression trials have excluded these patients. 41 The impact of unrecognized and untreated depression on medically ill patients is not limited to the psychiatric morbidity of an altered mood. It has been shown to adversely affect length of hospital stay, selfcare abilities, and possibly even survival. 4 It likely affects the ability to stop smoking and abstain from alcohol. 44 It also negatively impacts compliance with medical treatment. This was demonstrated in a study examining the degree of acceptance of adjuvant cytotoxic drugs in women with breast cancer. 45 The women in the study who were depressed accepted the adjuvant therapy only 51% of the time compared to 92% in the non-depressed subjects.
Thus, depression in patients with HNC has profound implications for the overall well-being of the individual and strategies to prevent depression are critical.
B.1.b Impact of HNC on Treatment Outcomes
The traditional end-points of clinical cancer studies have been response rate and survival. In the past decade health-related quality of life has emerged as another important outcome measure in the comprehensive care of the cancer patient. Health-related quality of life includes the physical, psychological, functional, and social well-being of an individual and is particularly relevant to the care of patients with HNC. 25 The structural and functional deficits associated with treatment of this cancer have profound physical and psychosocial implications, potentially diminishing health-related quality of life. 14, 25 Clinical depression is one of the few factors consistently found to be an independent predictor of health-related quality of life during treatment for HNC and for years thereafter. 25, 26, 33, 46 Patients who are clinically depressed when the diagnosis of cancer is made are more likely to have a poor health-related quality of life during and after treatment. 14, 45 While the relationship between depression and health-related quality of life in terms of cause and effect is complex and incompletely understood, diminished quality of life is reflected in increased severity of symptoms and poorer physical, psychological, and social functioning. 46 Basic science laboratory research provides support and rationale for the clinical work proposed. Exposure to severe, inescapable stress results in subsequent behavioral depression, termed "learned helplessness." Learned helplessness is considered to be an animal model for clinical depression. Learned helplessness has been extensively studied in the rat, but also can be demonstrated in a range of other species, including humans. In the rat, learned helplessness can be prevented by treatment with antidepressant drugs, including the SSRIs, if these agents are administered in repeated doses prior to inescapable stress exposure. Antidepressants given prior to stress maintain levels of cortical serotonin and prevent stress induced depletion of serotonin in proportion to prevention of stress induced depressive behavior. 47 If learned helplessness models are relevant to clinical depression induced by the stress of the diagnosis and treatment of cancer, prior treatment with antidepressants should prevent subsequent depression in humans.
Investigations into the psychological aspects of HNC have primarily focused on establishing the prevalence of and predictive factors for psychiatric morbidity. There has been little emphasis on applying interventions aimed at improving psychiatric and psychological outcomes in order to decrease suffering and improve health-related quality of life. Remarkably, there are no published studies evaluating the effects of antidepressants on clinical depression and their impact on health-related quality of life in HNC patients.
B.2.a. Treatment of Depression Associated with HNC and Other Cancers
Treatment options for clinical depression include psychotherapy, pharmacological therapy and electroconvulsive therapy. Medication and/or psychotherapy are effective in the majority of medically ill patients suffering from mild to moderate depression. medications may be particularly advantageous for these patients, because they require less interaction on the part of the patient, and, furthermore, are readily available to non-psychiatric clinicians. Antidepressants are considered to be safe for the treatment of depression in cancer patients. 12, 13, [41] [42] [43] 48 The two main classes of medication utilized are selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants. The SSRIs have several advantages over the tricyclics including their generally favorable side effect profile and greater safety in overdose, which is relevant given the increased risk of suicide in HNC patients. 41, 43 Citalopram is a safe, efficacious SSRI with a favorable side effect profile, and minimal drug interaction potential, making it an attractive agent for the treatment of depression among patients with comorbid medical illness. 49 Thus, this study will focus on the use of the SSRI citalopram to prevent the development of depression in HNC patients.
Another potential benefit of using citalopram in HNC patients is that it may help these patients reduce their alcohol consumption. 50, 51 While citalopram has shown minimal effects on reducing problem drinking in general 49, 50 it may have a greater effect in this population if it can prevent depression since depression is known to adversely affect abstinence from alcohol. 44 Likewise, citalopram may also have some impact on smoking cessation though the data with SSRIs for this purpose is weak and most studies do not indicate a benefit. 52, 53 Preventing the occurrence of depression in these patients may prove singularly helpful since a cancer diagnosis by itself is associated with at least moderate reductions in smoking. 54 These potential benefits on substance use have not been examined in patients with HNC. While there is only minimal evidence to suspect that citalopram might have some impact on the use of these substances, given the complex interplay between depression, cancer, smoking and alcohol use, this possibility merits exploration in the context of the proposed study.
B.2.b. Review of the Treatment Literature Randomized Trials of Antidepressants Without a Placebo Control in Patients with Cancer:
As noted above, there have been no trials of antidepressant therapy in patients with HNC. There are remarkably few investigations of antidepressant therapy for the treatment of depression in any type of cancer patient. Non-placebo controlled, randomized trials include that by Purohit who conducted a 4-week trial in 39 depressed patients with a variety of cancers. These individuals were randomized to treatment with radiotherapy plus imipramine versus radiotherapy alone. Eighty percent of the combined group showed improvement on a global rating (based on the Hamilton Depression Rating Scale) 55 versus 42% of the radiotherapy alone group ( 2 = 17.09, p = .0019, our calculation based on Table 4 ). 56 A randomized comparison of the antidepressants fluoxetine and desipramine in depressed women with advanced cancer found both medications were effective in reducing symptoms of depression and anxiety. Patients taking fluoxetine also had greater improvements on several quality of life measures. 47 Pezzella compared paroxetine and amitriptyline in 179 depressed women with breast cancer. Both drugs demonstrated significant improvement as measured by the Montgomery Åsberg Depression Rating Scale (MADRS) 57 scale with paroxetine slightly better tolerated. 58 
Placebo-Controlled, Randomized Trials of Antidepressants in Patients with Cancer
There have been six placebo-controlled, RCTs for patients with depression and any kind of cancer. Razavi conducted a placebo-controlled, RCT of fluoxetine in 91 women with breast and gynecological cancers who had combined anxiety and depression. 59 Women in the fluoxetine group did significantly better on a measure of general psychopathology after 5 weeks of treatment but did not have a significantly better response rate on the main clinical outcome measure, the Hospital Anxiety and Depression Scale (HADS). 60 Significantly, more women taking fluoxetine dropped out of the study (33%). A major limitation of this study was the exclusion of women with severe forms of depression.
Two trials utilized the antidepressant mianserin (not available in the US) which proved more effective than placebo in reducing the severity and duration of depressive symptoms in women with cancer. 61, 62 Importantly, the mianserin groups had significantly fewer dropouts. In the first study, the authors analyzed a subgroup of patients with advanced breast cancer. Patients in the mianserin group had a significantly higher mean number of cytotoxic drug treatment courses and the number of premature dismissals requested by patients was lower. Mean total doses of cyclophosphamide, methotrexate and fluorouracil were significantly smaller for the placebo group. The authors stated that their preliminary results "suggest that antidepressant treatment tended to increase the proportion of responses to antitumor therapy…probably by mitigating PHS 398/2590 (Rev. 09/04) Page Continuation Format Page the action of behavioral factors that could lead to the interruption of antitumor therapy as a result of depression." A study of fatigue in women receiving chemotherapy for breast cancer also measured depression as a secondary focus. 63, 64 Patients who reported fatigue by day 7 following the second of at least four cycles of chemotherapy, were randomly assigned to receive either 20 mg of paroxetine or a placebo. Patients then completed questionnaires at home (depression questionnaires included the Profile of Mood States and Center for Epidemiologic Studies-Depression) to measure fatigue and depression. A total of 244 patients treated with paroxetine, and 235 patients treated with placebo had assessable data. Paroxetine significantly reduced depression as measured by the CES-D during chemotherapy but did not have a significant effect on fatigue. The authors concluded that up to half of cancer patients experience some degree of depression during the course of their diagnosis, treatment and recovery, and it has not been optimally treated.
Fisch and colleagues conducted a placebo-controlled trial of 20 mg of fluoxetine in patients with advanced cancer who had symptoms of depression on a two-item screening instrument. 65 They found significant improvements in the fluoxetine treated patients in quality of life and a significant reduction in depressive symptoms. Fluoxetine was well tolerated.
The Agency for Healthcare Research and Quality Evidence in summarizing the meager published data on treating depression in cancer patients concluded that "every study that used antidepressants and conformed to usual practices for antidepressant trials did…show benefit".
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They remarked on the "great opportunities for research in psychopharmacological interventions for depression co-morbid with cancer."
On the other hand, Musselman and colleagues recently reported the results of a negative trial in which a total of 35 female depressed outpatients with breast cancer were randomized to placebo, paroxetine or desipramine. There were no differences among the groups at endpoint. However, the patients who received placebo in this trial had an unusually high response rate (55%), and were found to have had less extensive disease, more use of sleeping medications and less prior exposure to chemotherapy suggesting lack of homogeneity among the assigned treatment groups. 
B.2.b. Preventing Depression: The Role of Prophylaxis
The above studies illustrate the potential value of treating clinical depression during cancer treatment. However, these studies all waited until depression was present before treatment was begun. An innovative approach to the prevention of depression in cancer patients has been reported in malignant melanoma patients undergoing treatment with high-dose interferon alpha. 68 Depression occurs in approximately 45% of patients receiving high doses of interferon alpha. In this study, patients were pretreated with paroxetine before receiving interferon alpha. The number of patients who developed depressive symptoms was 45% in the placebo group and 11% in the paroxetine group. Additionally, treatment with paroxetine significantly reduced the number of dropouts (5% in paroxetine group, 35% in the placebo group). This preliminary study suggests that prophylactic antidepressant use may prevent the development of depression in cancer patients at high risk for this disorder and reduce dropouts during treatment of the underlying cancer.
Although SSRIs have been extensively used prophylactically in psychiatric conditions such as recurrent depression 48, 69 and premenstrual dysphoric disorder, 70 the use of antidepressants as prophylactic agents in medically ill patients is an emerging field. In addition to the interferon prophylaxis study noted above, antidepressants have also been shown to help prevent depression following stroke. 71, 72 Patients with HNC are clearly a population at high risk for depression where prophylactic use of antidepressants might be particularly helpful. Depression and suicide occur at an alarming rate in these individuals and depression peaks in a relatively discreet period, 2 to 3 months after diagnosis, during the midst of treatment. 16, 26, 33 Waiting to begin treatment until depression develops is an unsatisfactory strategy given that antidepressants usually require 3 to 4 weeks to exert their therapeutic effect. This lag time may be too long to prevent depression from interfering with the course of treatment which suggests a need to test the hypothesis that prophylactic use of SSRIs can prevent depression in HNC patients.
Prophylactic treatments are commonly used for other medical conditions. Examples in current practice include the prophylactic use of benzodiazapines for alcohol withdrawal, beta blockers following myocardial infarction, and anticoagulants for patients with atrial fibrillation. [73] [74] [75] [76] Despite these treatments having known side-effects, they confer an advantage over no treatment. Prophylactic treatment must weigh the risks of the intervention against the risks of failure to treat or delayed treatment. The risks of SSRI treatment appear PHS 398/2590 (Rev. 09/04) Page Continuation Format Page reasonable, particularly when compared with the potential benefits of reducing the rate of depression, improving compliance and promoting a higher quality of life among these patients.
B.3 Summary and Rationale for Proposed Work
HNC patients are at exceptionally high risk for developing depression. In these patients, when corrected for stage of disease, the single most important factor in predicting success or failure of radiation therapy is delay in treatment, and depression has been shown to reduce adherence in patients receiving radiotherapy. 6, 7 Further, this group of patients is not likely (at least in the short term) to participate in psychotherapy, due to the morbidity associated with the disease and its treatment, as noted. In addition, it is difficult to determine precisely when the patients who become clinically depressed begin to suffer from symptoms of depression, and antidepressants typically require several weeks of administration for clinical efficacy. Thus, we believe prophylactic treatment in these patients is warranted. We propose a randomized, placebo-controlled, double-blind study investigating whether citalopram can prevent major depression and preserve quality of life in patients with newly diagnosed or recurrent head and neck cancer undergoing major surgical resection or radiotherapy, or a combination of surgery and radiation, radiation and chemotherapy, or all three.
Since prevention of depression with an antidepressant has never been studied in this high-risk HNC population or in any non-melanoma cancer group it seems critical to assess the impact of antidepressants on preventing depression in patients with HNC. Regardless of the results, this study will produce important information that is likely to improve patient care.
C. PRELIMINARY STUDIES C.1.a. The Investigators
The principal investigator, Dr. William J. Burke has extensive expertise in clinical trials and innovative approaches to the psychopharmacologic treatment of depression. The co-investigator for this trial, Dr. William Lydiatt, has a long-standing interest in maximizing quality of life in patients undergoing treatment for HNC. Dr Burke has been closely involved in clinical psychopharmacologic research. The Psychopharmacology Research Consortium at the University of Nebraska Medical Center, directed by Dr. Burke for the past 15 years, has conducted 38 clinical trials for treatments of major depression including studies evaluating electroconvulsive therapy, vagus nerve stimulation and 17 different compounds, including all of the currently available SSRIs. As examples of the innovation of the group, Dr. Burke and collaborators pioneered the concept of weekly dosing strategies for fluoxetine [77] [78] [79] [80] and have investigated the impact of depression and the effects of antidepressants on immune function in vivo and in vitro. [81] [82] [83] [84] The Psychopharmacology Research Consortium also has extensive experience in conducting depression trials across the age spectrum. Our site led enrollment in the NIMH-funded multi-center Treatment of Adolescent Depression Study (TADS) with 20% of the total sample.
The Given their extensive experience they have a long-term interest in and concern about depression in their HNC patients. Noting that patients and families experience substantial emotional turmoil after the diagnosis of cancer, they published a book on HNC entitled "Cancer of the Mouth and Throat, A Patient's Guide to Treatment." 22 This book contains information on the major forms of treatment, surgery, radiation and chemotherapy. Importantly, it includes chapters on the emotional and psychiatric aspects of cancer, follow-up care, end-of-life issues, pain management and control of depression.
The collaboration of the Psychopharmacology group with the HNC group began when the HNC team provided surgical support during a multi-center trial of vagus nerve stimulation (VNS) for the treatment of refractory depression. 85 Discovering a common interest in finding better ways to treat depression led these teams to perform a pilot study which is the basis of this application. 
C.1.a. Pilot Trial
The groups initiated a randomized, double-blind, placebo-controlled pilot study to evaluate whether depression could be prevented in patients with HNC. Subjects with HNC who were about to begin treatment for their cancer were randomized to receive placebo or flexibly dosed citalopram (20 to 40 mg a day) for 12 weeks, during which time they were evaluated every four weeks. Study medication was then tapered over a week and discontinued and patients were evaluated once more at 16 weeks. Analyses used a modified intent-to-treat sample which included all subjects who provided informed consent, were not depressed (Hamilton Depression Rating Scale, 55 HRSD < 15 at baseline) and were available for evaluation at the first post-randomization visit (4 weeks). Thirty-six subjects were randomized (18 in each group). Three subjects in each group were excluded because their baseline HRSD scores were > 15 (base rate of depression pre-intervention = 17%), one subject (placebo group) was deemed ineligible on the basis of a low Mini-Mental State Examination (MMSE) 86 score and one subject (placebo group) dropped out before completing baseline testing. One subject in the placebo group was excluded after missing the visit 1 evaluations due to scheduling problems and two subjects in the citalopram group did not return for visit 1 because of adverse events (one subject each had diarrhea and nausea). This left 23 in the modified ITT group (12 in the placebo group, 13 in the active group). Twelve men and 13 women, with a mean age of 61.2 (SD + 10.9) participated. Subjects did not significantly differ on age, gender, tumor grade, type or location. There were no differences in the number of HNC treatment modalities received (i.e. surgery, chemotherapy, radiation either individually or in combination). Twenty-two subjects were evaluated at week 12 of the study and 23 completed the study, 13 in the citalopram group, and 10 in the placebo group. The only subject who dropped out from the placebo group did so after week 4 due to hospitalization for severe depression. One citalopram subject was not available for the week 12 visit but did return for the follow-up visit at week 16. While the small sample size limits interpretation of the data, measures of psychiatric well-being all favored the group taking citalopram. The number of subjects who met criteria on our pre-defined cut-off (HRSD >15) on the Hamilton Rating Scale for Depression for clinically significant depression at any time during the 12 weeks of active study was 6/12 (50%) in the placebo group and two of 13 (15%) in the citalopram group (Fisher's exact p=0.097, see Figure 1 ). The percent of those whose HRSD was > 15 stayed roughly at 15% in the citalopram group throughout the study but increased to 50% in the placebo group at weeks 12 and 16. These numbers are very similar to the paroxetine interferon-alpha prophylaxis trial noted above. In that study, the number of patients who developed depressive symptoms was 45% in the placebo group and 11% in the paroxetine group.
The number of subjects who met criteria for major depressive disorder (MDD) at any visit (determined by the depression module of the Mini-International Neuropsychiatric Interview [ MINI]) 87 was 6 of 12 (50%) in the placebo group and 3 of 13 (23%) in the citalopram group (Fisher's exact p=NS, see Figure 2 ). More than twice as many patients in the placebo group met criteria for MDD on the MINI at endpoint of the acute study (17% vs. 40% at week 12, see Figure 2) .
Additionally, no patients in the citalopram group became suicidal (suicide module of the MINI) during the 16 weeks of study, compared to two in the placebo group.
Quality-of-life, measured by the University of Washington Quality-Of-Life Scale (UW-QOL), 88 deteriorated in both groups from baseline but less so in the citalopram group (see Figure 3) . UW-QOL median change from baseline to week 12 was 18 points in the citalopram group and 30 points in the placebo group (p=ns). At week 16 the decline was 7 points in the citalopram group and 32 points in the placebo group, (Wilcoxon p-value = 0.14). The placebo group continued to decline at follow-up, while the citalopram group improved.
Overall mood state, as estimated by CGI-severity 89 score was "Mildly ill" or greater in 25% of citalopram-treated participants at week 12 and in 15% at week 16 compared to 50% and 60% of the placebo treated patients, respectively. (see Figure 4) No patient in the citalopram group had a CGI-S score of greater than mildly ill at any point during the study. As in the quality of life measurements, the treatment group showed improvement at 16 weeks compared to worsening scores in the placebo group. 40% of the patients presenting for treatment came from rural or frontier areas. Many of these patients wished to participate in our pilot trial but were unable to return long distances for the monthly visits. We were unable to include these rural patients because we had not established a method for remote measurement of their mood state.
One surprise in the pilot was the relatively low rate of alcohol and tobacco use among the subjects. Six subjects in each group were using alcohol at study entry. Five of 6 subjects in each group stopped all use of alcohol at the conclusion of the study. Only 2 subjects in the active group and 4 in the placebo group were using tobacco at study entry. Over the course of the study one subject in each group stopped tobacco use. These small numbers do not allow for significant interpretation with regard to drug or placebo effect.
It is not clear why the number of tobacco and alcohol users was so low in the pilot study. Many of the subjects had quit smoking prior to study entry, sometimes in the week or two prior. Another possibility is a selection bias evident in research trials towards more educated and female participants, particularly since tobacco use is typically less prevalent among educated individuals and among females with HNC. Another explanation may be the bias away from rural or frontier areas as discussed above. There may be a higher rate of tobacco use in these subjects who could not participate secondary to the large amount of travel required.
We also found that the clinical interview we used in the pilot study proved burdensome due to the degree of illness experienced by these patients. Many requested a more focused, briefer set of outcome measures. We also found that depression was severe enough to require prolonged treatment: many patients at the end of the placebo-controlled study (week 12) were still experiencing depression.
In the proposed study we have focused and simplified the clinical measures by taking advantage of recent advances in the use of self-report measures to capture mood. We anticipate reducing participant burden and capturing more subjects from rural areas. We have increased the flexibility for subject interviews and data collection. We have also extended the length of the proposed placebo-controlled trial (from 12 weeks to 16 weeks) and follow-up (from 4 to 12 weeks following the placebo-controlled study period) to better capture the natural arc of depression experienced by this patient population.
The results of the pilot study have been selected as oral presentations at national meeting of the American Head and Neck Society 90 and the Academy of Psychosomatic Medicine meeting. 91 The importance of the issue of depression and suicide in patients with HNC and our proposed approach was also discussed in a recent feature in the Journal of the American Medical Association. To determine if treatment with escitalopram, compared to placebo, will reduce the risk of developing depression among non-depressed, patients with HNC who are about to begin treatment using a randomized, placebo-controlled, double-blind trial.
Hypothesis: Among non-depressed patients embarking on treatment for HNC, we hypothesize that escitalopram will reduce the incidence of major depressive disorder from 40% to 20%.
D.1.a. Study Design to Test Primary Specific Aim
This study will be conducted in two phases. The acute phase will be a prospective, randomized, placebo-controlled trial of escitalopram, in all adults newly diagnosed or with recurrent cancer of the oral cavity, pharynx, larynx, paranasal sinuses or major salivary glands who are not depressed but who are undergoing treatment with surgery, radiotherapy and/or chemotherapy. In the follow-up phase, patients will be tapered off of the study medication and followed once monthly over three months.
D.1.b. Patient Population Subject identification:
All subjects who are seen at the Head and Neck Cancer clinics at the University of Nebraska Medical Center (UNMC) and Nebraska Methodist Cancer Center (MCC) for treatment of new or recurrent cancers will be considered for possible participation. A screening record will be kept of all patients who are approached for possible participation. Certain de-identified information will be recorded for all patients who are approached, in order to determine the representativeness of the recruited sample. Information which will be entered onto a screening form will include: age, sex, race and ethnicity. Any reason they spontaneously offer about why they choose not to participate will be recorded. They will not be queried about the reason for choosing not to particiapte to avoid any possibility of unintentional inducement To facilitate enrollment the clinical research nurse will be present at each clinic throughout the week (a total of 9 half-day clinics per week) and will evaluate every new patient as a potential subject. Bi-weekly head and neck tumor conferences will also be used to identify potential subjects. The study will be explained to potential subjects and written informed consent will be obtained prior to study entry.
D.1.c. Inclusion / Exclusion Criteria:
Inclusion criteria: 1) age 19 or older (legal age of majority in Nebraska) 2) those with newly diagnosed or recurrent epidermoid cancer of the head and neck 3) those whose cancers are stage II or greater 4) those able to read and write English (required for informed consent document and self-ratings). 5) those willing and able to provide informed consent.
Exclusion criteria:
1) those who meet diagnostic criteria for major depression, schizophrenia or bipolar illness on the MINI 87 at the baseline interview, 2) those who score less than 24 on the Mini-Mental State examination, 86 3) those judged to be actively suicidal or pose a risk of violence to others, 4) those who are currently taking an antidepressant medication, 5) those with allergy or hypersensitivity to escitalopram or to other SSRIs, 6) those who have undergone treatment with monoamine oxidase inhibitors within 14 days or other antidepressants within 1 week, 7) female subjects who are pregnant or nursing, 8) females of childbearing age who are not practicing a reliable method of birth control 9) those that have had an adequate cancer operation, radiation or chemotherapy in prior six months. 10) those whose cancer of the head and neck is a melanoma or lymphoma (different natural history and treatment required) 11) those who are unable or unwilling to return to the clinic for the end of the acute study (weeks 16) and end of the follow-up study (week 28) 12) current participation in another research study involving a therapeutic intervention
D.1.d. Presumed differences between those who choose to participate and those who refuse
Based on our pilot study experience we expect that the most likely reason that patients will refuse to participate is the possibility of receiving a placebo. Also, although men are more likely to have HNC, in our pilot study we enrolled roughly even numbers of men and women. We believe that this was due to men being less willing to participate though we did not formally record the reason that patients declined participation. We suspect that an additional consideration was that persons with active substance abuse/dependence were more likely male and also less likely to be interested in participation.
Overall however, we believe that these inclusion/exclusion criteria will result in a representative sample of patients with HNC. We will record the reasons why eligible patients refuse to participate in this trial.
D.1.e. Study Intervention
Following subject informed consent and randomization, the study medication will be dosed at one pill for the first week (either placebo or escitalopram 10 mg daily) and then increased to two pills/day (two placebo pills or two escitalopram 10 mg daily) until week 16 when the study medication will be reduced to one pill per day and then stopped one week later. The dosage of the study medication may be decreased to one pill/day at any time because of an adverse event. Participants will be assigned a treatment number and dispensed a closed, labeled bottle of study medication and instructed to take the medication each evening beginning on the day the study medication is dispensed. However, dosing may be switched to the morning if preferred. All study medication will be administered as a single daily dose. The contents of the pills may be placed in applesauce, ice cream, or water for subjects unable to take pills (thus may be administered through a gastrostomy tube).
Subjects will be instructed to return all unused medication at each visit. Pill counts will be performed at the end of weeks 4, 8, 12 and 16. Outcomes of primary interest during this phase of the trial are rate of major depression, the number of breaks in prescribed cancer treatment, the number of subjects prematurely discontinuing prescribed cancer therapy, quality of life and use of alcohol and tobacco. At 16 weeks all subjects taking two tablets daily will have their dose reduced to one pill daily for one week then stopped. Those who are taking only one tablet will have their medication stopped at the end of 16 weeks.
In the follow-up phase, subjects who complete the acute phase will be followed at 20, 24 and 28 weeks in order to gauge potential long term outcomes of the acute phase intervention. Outcomes of primary interest during this phase of the trial are the rate of major depression, need for intervention for depression, quality of life, use of alcohol and tobacco and need for hospitalization for any reason.
All patients will receive the standard clinical psychosocial interventions throughout the study, primarily education and counseling. Education materials will include the book, "Cancers of the Mouth and Throat" 22 and specific instructions concerning the prescribed cancer therapy. Counseling will be done by the physicians and nurses as needed. Per the standard practice of this clinic, subjects will be offered the opportunity to join a support group which meets monthly, but will not receive formal psychotherapy. Patients will be asked not to enter into formal psychotherapy during the acute phase of the trial but may do so during the follow-up phase.
D.1.f. Rationale for Design: Why Not Treat Only Patients at Risk for Depression?
An alternative approach to prophylactically treating all patients who are not depressed would be to instead treat only those at risk for developing depression. There have been attempts to predict who will become depressed during treatment for HNC. Various factors have been proposed as possible predictors of elevated depressive symptoms after HNC treatment with the most important factors including baseline depressive symptoms, [93] [94] [95] [96] [97] [98] degree and type of social support, 93, 94 tumor-related physical characteristics [99] [100] [101] [102] [103] [104] and sex. 102, 103 However, with the exception of baseline depressive symptoms and social support, none of these other factors has shown a consistent relationship. [103] [104] [105] [106] In the proposed trial all patients found to be depressed at the time of baseline evaluation will be referred for possible treatment and are thus outside the scope of this proposal. Our contention is that once these patients with depression are eliminated the only other unambiguous baseline variable which predicts depression is social support and the contribution of that factor is relatively small. 93 In our pilot study despite the exclusion of patients with depression at baseline we still found that half of the participants in the placebo group developed MDD at some point during the trial.
D.1.g. Choice of Antidepressant
Escitalopram was selected as the study medication based on evidence of its efficacy, safety, favorable side effect profile, ease of discontinuing treatment, ease of administration as a single daily dose, safety in older adults and in medically fragile patients, few dosage adjustment steps and minimal drug interaction potential. 48, 107 Also, escitalopram is now available as a generic formulation. Escitalopram has been used in one open label trial in ambulatory cancer patients who had elevated scores on a depression screening scale. Escitalopram reduced depressive symptoms, improved quality of life and was well tolerated. 108 In our pilot study citalopram showed a trend toward preventing MDD and was well tolerated with only two patients dropping out due to gastrointestinal side effects.
Other medications were considered. Fluoxetine and paroxetine were rejected on the basis of their potential for cytochrome P450 inhibition in this group of medically ill patients. Sertraline has a profile similar to escitalopram but its dosing is more complicated with a range of recommended dosing from 50 to 200 mg/day. Escitalopram, the s-isomer of citalopram, has similar advantages of citalopram. Mirtazapine was also considered given its similarity to mianserin (which, as shown above, has demonstrated efficacy in treating depression in patients with cancer) and its potential to possibly stimulate appetite in this population of cancer patients. However, its potential for sedation was considered to outweigh these possible advantages. Likewise, the propensity for venlafaxine to cause nausea and its formulation as a sustained-release capsule made it impractical for this population. Duloxetine was not considered due to a comparatively limited database.
D.1.h. Rationale for Study Duration
Sixteen weeks was chosen for the acute study because it encompasses the time needed for cancer treatment, the period when patients are most likely to be depressed. 35 Given that patients by definition are not depressed at baseline, it is a relatively safe period to treat a patient with placebo who may develop depression. 12 weeks of follow-up after the acute study was chosen in order to have sufficient time to judge the impact of withdrawal of prophylactic treatment for depression on treatment completion and to detect developing depression.
D.1.i. Randomization:
Patients will be randomized in a 1:1 ratio to either escitalopram or placebo, stratified for gender, stage of disease (to ensure equal assignment of stage II patients) and initial treatment approach (i.e., surgery versus other types of treatment). Assignment will be made according to a randomization schedule generated by our statistical consultant. Study subject will be assigned a unique study identification number that will be used on all study data forms, and other study records. Patient names, initials and/or hospital IDs will not be used as protocol identifiers.
Records on randomization and study medication will be kept in the research pharmacy at the University of Nebraska Medical Center. The UNMC research pharmacy will provide the medications to the clinical research nurse to give to the subjects. This medication will be taken to the appropriate clinic for distribution to the subjects.
D.1.j. STUDY SCHEMA:
Principal 
D.1.k. Outcome Variables for Specific Aim 1: Depression The Quick Inventory of Depressive Symptomatology (QIDS-SR-16 and QIDS-C16)
The measures chosen for the study reflect the unique population being studied. Our instruments were chosen with a number of perspectives in mind including our experience in the pilot trial. The pilot trial brought to our attention specific needs of this population including the need for a measurement process: 1) that was not burdensome to these patients who can be quite physically ill, 2) that used a primary measure which could be self-rated (given the difficulties with verbal communication that some of these patients experience), and 3) that allows remote assessment, given the distance many of our patients live from the research clinic. For these reasons, we chose the QIDS-SR16 as our primary outcome measure. The QIDS-SR16, which is a brief, self-rated depression measure derived from the IDS 109 should be an ideal depression measure given the needs of our population as stated above. The QIDS interviews were developed to improve on available clinician and patient ratings by providing equivalent weightings for each depressive symptom, provide clear anchors for each item, include all of the DSM-IV-TR criterion required to diagnose MDD, and provide matched clinician (QIDS-C16) and patient ratings (QIDS-SR-16).
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The QIDS-SR16 includes 16 items which cover all nine of the core DSM-IV-TR symptom domains needed to diagnose major depression. 109, 111, 112 Patients rate each DSM-IV-TR symptom as not present, mild, moderate, or severe over the prior seven days. In non-psychotic outpatients with major depression and without overt cognitive impairment, the QIDS-SR16 makes fewer demands on the research subject while producing results as good, or in some cases better, than those with the HRSD17 109, 112 and HRSD24. 109, 113 Self-reports have been increasingly used in clinical trials and the FDA now accepts self reported depressive symptoms as primary outcomes for registration trials (including the QIDS-SR16). Each item of the QIDS-SR16 and QIDS-C16 is scored from 0 to 3 for a total score range of 0 to 27. HRSD17 scores can be converted to QIDS-SR16 scores by multiplying the HRSD17 score by 0.8.
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The QIDS scales take less than 10 minutes to complete and can be done by the subject at home if they are unable to travel to the clinic. We therefore chose not to use the HRSD17 as we did during the pilot study because of its lack of coverage of DSM core symptoms, its relative complexity, the presence of confounded items and a longer time needed to administer. 109, 114 The QIDS-C16 is the matched clinician-rated measure of depressive symptoms. The QIDS-C16 uses the same questions as the QIDS-SR-16 and thus covers the core symptoms of depression used to diagnose an episode of major depression. The QIDS-C16 and QIDS-SR-16 are highly correlated. Both QIDS versions are accurate measures of symptom severity and are sensitive to change. 109, 115 Indeed, the QIDS-SR-16 was recently used as one of the principal outcome measures in the large NIMH sponsored STAR*D trial which evaluated outcomes of patients treated for depression with citalopram. 
D.1.l. Sample Size Calculation:
Among non-depressed patients embarking on treatment for their HNC, we hypothesize that escitalopram will reduce the occurrence of depression from 40% to 20% at week 16 (end of acute study). These estimates are based on literature suggesting that 40% of patients undergoing treatment for HNC will become depressed 2, 3, 20 and confirmed by our pilot data which showed that 40% of patients in the placebo arm at the end of the RTC had MDD (figure 2 above) versus 17% of patients taking citalopram.
The primary outcome variable will be the Quick Inventory of Depressive Symptomatology-Self Rated16 (QIDS-SR-16) where scores > 11 will be considered evidence of moderate or greater depression. 109 The rating scales will be measured at an initial assessment, with follow-up observations scheduled for weeks 2, 4, 6, 8, 10, 12 , and 16 weeks (while in the randomized clinical trial) and again at weeks 20, 24 and 28. The primary focus of the efficacy analysis will be on the time to moderate or greater depression (i.e., > 11 on the QIDS-SR-16 between the treatment groups between randomization and week 16 (during active, placebo controlled, treatment). The study has been designed to have 90% power (testing at the 5% level of statistical significance [two-sided]) to detect a difference in depression rates at week 16 of 20% (20% in the subjects randomized to escitalopram and 40% in those randomized to placebo). Assuming the time to moderate or greater depression follows an exponential distribution, accrual of 1 evaluable patient (i.e., not lost to follow-up) per week and 16 weeks of follow-up, a sample size of 150 (75 per treatment) is required. As shown in Figure  6 , we will need to randomize 188 patients to achieve 150 patients that are not lost to follow-up. In this context, patients lost to follow-up are patients for whom no post-randomization follow-up observations are available.
D.1.m. Statistical analysis of specific aim 1:
To analyze the primary endpoint of interest, we will compare the time to moderate or greater depression between the two treatment groups using the stratified log-rank test. All efforts will be made to collect week 16 data on all study subjects, even those who have withdrawn from study medication (but who continue to provide consent for study procedures and data collection). Cox proportional hazard regression will be used to compare the two treatment groups after adjustment for stratification factors and other baseline characteristics thought to predict the outcome of interest.
Data on the primary endpoint (QIDS-SR-16) will also be analyzed using generalized estimating equation (GEE) techniques. 
D.1.n. Interim monitoring of the primary study endpoint:
An independent Data and Safety Monitoring Committee (DSMC) will be established and comprised of University of Nebraska Medical Center (UNMC) faculty with knowledge and experience relevant to the conduct of this study (oncologist, psychiatrist, statistician, etc), but with no involvement in the proposed study, either as a investigator or as a participant in the treatment of the study subjects.
Formal interim analyses of the data from this study will be performed at the time that 25%, 50% and 75% of the expected study subjects have reached study week 16. We will use an O'Brien-Fleming monitoring boundary 119 (truncated at 3 standard deviations) to assess whether the interim results are sufficient to conclude that escitalopram is effective in reducing depressive symptoms. We will also apply a futility monitoring rule at the time of the three interim analyses. If at any of these analyses, the data are not consistent with a 20% difference in the percent of subjects with moderate or greater depression at a confidence level of .995 (99.5% confidence interval for the true difference dose not include 0.20), the study will be recommended for early termination. The CGI-S and the CGI-C are global assessments of depression which provide an overall rating of the severity of depression and any change in depression respectively on a simple 7-point scale. 3) Tolerability of study medication treatment: a) rate of discontinuation for adverse events b) FISER-GRSEB (Frequency Intensity of Side Effects Rating/Global Rating Side Effects of Burden) 110 To measure side effects that may result from treatment with study medication we will use the FISER/GRSEB. The FISER/GRSEB is a self-report measure that focuses on the last seven days and is comprised of three global ratings which encompass all side effects to study treatment. One item rates frequency, another rates the intensity of side effects encountered in the prior week that the participant believes were due to the antidepressant treatment, and the third asks participants to estimate the overall burden or degree of interference in day-to-day activities and functioning due to the side effects. Each item uses a 7-point Likert-type scale rated from 0 (i.e. no side effects) to 6 (i.e. intolerable) and takes less than five minutes to complete. 4) Clinical, demographic and prior treatment history: Demographic information will be recorded including age, gender, education, ethnic background/race (self-described). We will also record prior psychiatric history specifically recording history of MDD (age at first onset, number of depressive episodes), any history of treatment for MDD and family history of depression. 5) PRISE (Patient Rated Inventory of Side-Effects) : 7 item assessment of the occurrence of side effects over the past week in the following symptom domains; Gastrointestinal, Heart, Skin, Nervous System, Eyes/Ears, Genital/Urinary, Sleep, Sexual Functioning, and Other 6) Cancer Specific Measures: Weight will be monitored at each study visit along with routine vital signs. Site of recurrence, mortality and cause of death will be obtained and recorded. Since treatment for head and neck cancer is dependent on PHS 398/2590 (Rev. 09/04) Page Continuation Format Page many factors including site, stage, medical status and others, we have elected not to stratify for it in our randomization. In addition, depressive symptoms do not correspond to treatment type. 19 All treatments will be recorded and used in secondary analyses. Tumor type, stage and site will also be obtained for secondary analysis.
D.1.o. Secondary Outcome Variables for
D.1.p. Stopping Rules and "Treatment Failures":
Those patients who score >11 points on the QIDS-SR will be considered "treatment failures" with respect to the primary endpoint (i.e. prevention of depression) and discontinued from the study. Likewise, patients who qualify for a diagnosis of MDD on the MINI module or develop significant suicidal ideation/intent (score = 3 on item 12, "Thoughts of Death or Suicide" on the QIDS-SR-16 or QIDS-C16 or greater than 8 points on the suicidality module of the MINI) will be also considered "off-protocol" and will be discontinued from the study. Treatment assignment will remain blinded.
When a subject is identified as meeting criteria for depression or to be suicidal, the research clinician who makes that determination will notify the treating surgeon (Dr. William or Daniel Lydiatt or Dr. Alan Richards or Dr. Oleg Militsakh or Dr. Russell Smith) who will make further treatment recommendations on a case-by-case basis. Subjects will be eligible to receive any depression treatment they wish to pursue and will be provided referrals if they desire. Psychiatrists at both institutions are strongly supportive of the study and willing to provide consultation to these patients as needed (see Appendix, letters of support from Drs. Matthew Egbert and Jane Theobald).
Those patients who first meet criteria for depression during the follow-up phase of the trial will be treated in the same fashion.
In the unlikely event that a participant reaches the end of the acute phase and decides that they do NOT want to have the study medication tapered and stopped they will be dropped from the study and referred for treatment outside the study.
D.1.q. Participation at a Distance
Approximately 40% of patients who are treated in the HNC clinics come from outside the immediate Omaha metropolitan area. The population of the Omaha metropolitan area is greater than 800,000 persons but is surrounded by counties in Nebraska and Iowa that are sparsely populated and where access to mental health services and specialty cancer care are not available. For many of these individuals, returning to the HNC clinic for frequent visits in a clinical trial is simply too burdensome. Consequently, in our pilot trial these patients were excluded. We intend to specifically include these patients from more rural regions where travel to the clinic to participate in this study may represent an obstacle to participation. This goal will be facilitated by interventions and follow-up being conducted by mail and phone. In the last several years, many studies have shown the utility of this approach for patients with depression and other medical illnesses. 58, 59 To encourage these subjects to participate we have chosen our outcome measures to be self-report and/or telephone administered measures and have reduced the number of required face-to-face visits (baseline, end-of-acute study -week 16, and end of follow-up study -week 28. This reflects the typical visit frequency of patients returning to the HNC clinic for after-surgery cancer treatment follow-up. While all patients will be encouraged to make every visit, for those who can not make the interim visits ratings will be conducted by a combination of phone follow-up (clinical management and clinician-based ratings i.e. QIDS-C16, MINI depression and suicide modules, CGI-I and CGI-S) and mail (QIDS-SR16, UWQOL, FIBSER, alcohol/ and tobacco use and study medication). Additionally, this plan will enable us to gain information about this intervention in an underserved rural population.
Study medication and rating scales will be sent by registered mail along with a mailer to return unused study drug. The research coordinator will contact the patient to remind them to complete and return the forms and to conduct the QIDS-C16, MINI modules and the CGI scales. Adherence to treatment for the HNC and use of alcohol and tobacco will be noted. For those unable to communicate by phone, a collateral source for information will be identified in order to ensure the rating scales are completed, that medication is received and taken and to help identify problems, answer questions and improve adherence to the study regimen. The MINI is a brief, structured diagnostic interview for use by health information technicians in clinical and research settings. (Sheehan, 1998) The MINI provides broad coverage of psychiatric diagnoses according to DSM-IV and has been used very widely in psychiatric research. The clinician-rated version will be used in this study. Studies of the MINI show acceptable reliabilities and specificities and it was chosen over the Structured Clinical Interview for DSM-IV axis I diagnoses (SCID) primarily because it is shorter (20 minutes), thus easing patient burden. The MINI was used in the pilot study and was tolerated. The MINI covers a variety of psychiatric disorders of particular interest to this study including Major Depressive Episode (current and past), suicidality (in past month), and alcohol abuse/dependence (past 12 months).
D.1.r. Baseline Psychiatric Interview
D.2. Specific Aim 2:
To determine if escitalopram treatment, compared to placebo, results in improved quality of life for patients with HNC as determined by the University of Washington Disease Specific Quality of Life Questionnaire.
Hypothesis: We hypothesize that escitalopram will significantly impact quality of life as measured by the University of Washington Disease Specific Quality of Life Questionnaire.
D.2.a. Outcome Variables for Specific Aim 2: Quality of LIfe
The University of Washington Quality of Life Scale (UW-QOL) 88 The UW-QOL questionnaire is a self-administered scale designed specifically for head and neck patients. It is self-administered and takes less than five minutes to complete. The tested domains include: pain, disfigurement, activity, recreation/entertainment, employment, eating/chewing, eating/swallowing, speech and shoulder disability. The UW-QOL has been shown to have excellent psychometric properties and is acceptable to patients in the midst of treatment for HNC because it is concise and specific to their illness.
88
D.2.b. Statistical Analysis of Specific Aim 2:
To analyze the UW-QOL scores, we will compare the difference from baseline between the two treatment groups measured at protocol week 16 using an ANOVA model. For those study subjects who are unavailable for week 16 testing, we will use multiple imputation techniques to impute values for their week 16 results. We will also employ GEE techniques to analyze specific aim 2. UW-QOL scores will be obtained at the same time the QIDS-SR-16 is obtained, and analysis of changes in these scores over time and differences in the distribution of these scores between treatment groups will follow the analytic outline provided in specific aim 1.
D.3. Specific Aim 3:
To determine if prophylactic treatment with escitalopram, compared to placebo, will improve HNC treatment adherence including premature discontinuation of therapy.
Hypothesis: We hypothesize that escitalopram will significantly reduce prospectively documented breaks in treatment and premature discontinuation of therapy.
D.3.a. Outcome Variables for Specific Aim 3: Treatment Adherence
The UNMC Treatment Adherence Schedule (see Appendix) To determine if subjects who receive escitalopram have significantly better treatment adherence than those taking placebo, we will document any treatment breaks and/or premature discontinuation of therapy through prospective accounting of treatment course deviations from the prescribed therapy as dictated by the treating physicians. The three primary modalities of HNC cancer therapy are surgery, radiation therapy and chemotherapy in combination with radiation therapy or further combinations of all three. At the end of the study, we will evaluate whether each of these modalities was completed. A multi-disciplinary tumor board is PHS 398/2590 (Rev. 09/04) Page Continuation Format Page utilized to define prescribed therapy for all patients in this trial. This will be used as the basis for determining if the prescribed therapy is completed. Surgery is recommended as a specific operation and the patient either agrees or declines. We will therefore use a simple yes or no to completion of prescribed surgery. We will also record the dates when surgery was offered and when it took place.
Chemotherapy is only given with radiation in the curative setting. The addition of chemotherapy to radiation has been clearly demonstrated to improve overall disease control and survival. Data is incomplete on the impact of missed cycles but completion of the prescribed number of cycles of chemotherapy appears important to achieving improved disease control. Furthermore, depression may influence whether the patient starts a given cycle. We will therefore determine whether all of the prescribed cycles were completed as a yes or no response and also determine the percentage of cycles completed. Dates will also be recorded when chemotherapy was scheduled to commence and when it actually started. Dose reductions in chemotherapy will not be tracked since these are primarily a function of hematologic parameters directly related to chemotherapy and not clearly associated with whether the subject is depressed or ultimately on survival.
Disease control with radiation therapy is dependent on overall treatment time such that the fewer elapsed days between starting and completing radiation the better the survival in an essentially linear fashion. Total dose is also important in survival. We will determine overall time to completion as a percentage of prescribed days compared with actual days. 100% will indicate the subject had no breaks in treatment and completed the prescribed therapy. Premature discontinuation will be counted if the subject drops out prior to finishing the prescribed dose and scored as either a yes or no. Pretreatment therapy plans from the dictated clinician's notes will be used to document prescribed therapy and will be prospectively recorded in the data collection forms.
D.3.b. Statistical Analysis of Specific Aim 3:
The measures of treatment adherence will be compared between the randomization arms using the chisquare test for the binary measures (e.g., completed prescribed operation) or the Wilcoxon rank-sum test for the ordinal measures (e.g., number of chemotherapy cycles completed). The Wilcoxon rank-sum test will also be used to compare the proportion of treatment (chemotherapy or radiation) completed between the two arms. In addition to these univariate analyses, logistic regression analysis will be used to compare treatment adherence between the randomization arms after adjustment for patient and disease characteristics.
D.4. Specific Aim 4:
To determine if prophylactic treatment with escitalopram, compared to placebo will reduce the use of alcohol and tobacco.
Hypothesis: We hypothesize that escitalopram will significantly reduce the use of alcohol and tobacco products.
D.4.a. Outcome Variables for Specific Aim 4: Alcohol and Tobacco Use
Alcohol and tobacco use are known risk factors for HNC. Our pilot data suggested almost half of the participants used alcohol at study entry which is in line with other studies. 120 Eighty-three percent of subjects in both groups of the pilot study had stopped using alcohol at the final treatment visit. Because of the significance of alcohol and tobacco use in HNC and the paucity of data on the natural history of users during therapy as it specifically relates to depression and treatment with escitalopram, we feel prospective collection of data is essential to shed light on this area for future investigation. We seek to minimize subject time expenditure while maximizing useful data in this population. Furthermore, in the follow-up study data on recidivism will be recorded.
The Tobacco and Alcohol surveys
The AUDIT 121 and Fagerstrom 122 are self-administered surveys designed to monitor the use of tobacco and alcohol products at baseline, at 16 weeks and at 28 weeks. The AUDIT was developed by the World Health Organization to identify persons whose alcohol consumption has become hazardous or harmful to their health. AUDIT is a 10-item screening questionnaire with three questions on the amount and frequency of drinking, three questions on alcohol dependence and four on problems caused by alcohol. Total scores range from 0 to 40 and a score of 8 or more indicates a strong likelihood of hazardous or harmful alcohol consumption. The Fagerstrom test for nicotine dependence is a 6-item scale which has a range of 0 to 10. Usually patients who score 6 or more may need additional help in quitting smoking. Each survey takes approximately five minutes to complete and is self-rated. We will supplement the information from the AUDIT and Fagerstrom with our own short, self-administered, study specific questionnaire to monitor the use of tobacco and alcohol during weeks 4, 8, 12, 20 and 24. (see the Appendix) These less time consuming, self-rated surveys will be used to supplement the main measures obtained using the AUDIT and Fagerstrom.
D.4.b. Statistical Analysis of Specific Aim 2:
The AUDIT and Fagerstrom surveys will be analyzed in a similar fashion to the UW-QOL scores as described in Section D.2.b. GEE methodology will be used to analyze the responses to items on the study specific questionnaire. The analysis of the change in these responses and differences in the distribution of these scores between randomization arms will be performed as described in Section D.1.i. Table 2 below)
D5. STUDY TIMELINE AND SUBJECT FLOW (See
The initial months of Year 1 will be used to set up the program, begin to train evaluators and clinicians, prepare study forms, establish the study database, and finalize IRB approvals at the University of Nebraska Medical Center and the Nebraska Methodist Hospital. We will also purchase escitalopram and prepare blinded medication kits for the study.
Enrollment will begin in the third month at a rate of approximately one patient randomized per week (we expect 60 to be randomized each 12 months and 80% of these to be evaluable for the endpoint -48 subjects per year -see Figure 6 above for details). With a final goal of 150 evaluable subjects, we will need to randomize a total of 188 patients and recruitment will require just over three years (37 months) .
The last subject should be enrolled at the end of 39 months and will complete the RCT phase of the trial 16 weeks later at month 43 and the open-label phase at month 46.
We will initiate data analysis of each phase of the study as it closes. Dissemination of the data will follow and the results will be used to prepare the next stage of study for this population. 
